Kestra Medical Technologies, Ltd. KMTS R2K
Company Overview
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest; and a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
Why Investors Should Care
Revenue has grown at a 115.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.16.
Recent Developments
- Apr 2025 Revenue of $59.81M (+115.1% YoY); net profit $-113.81M.
- Trailing 12 Months Year-on-year growth — revenue +62.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 115.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 115.05% |
| 1 Year: | 62.70% |
Stock Price Performance
| 1 Year: | +56.71% |
| 6 Months: | -1.02% |
| 3 Months: | +28.89% |
| 1 Month: | +20.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.67 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 115.1% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KMTS Kestra Medical Technologies, Ltd. R2K | 24.18 | -4.43 | $1.41B | 0.00% | -41.27% | -92.65% | 115.05% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2024 | Oct 2024 | Jan 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|
| Revenue | 12.78M | 14.71M | 15.09M | 19.37M | 22.57M | 24.55M |
| Gross Profit | 4.20M | 5.83M | 6.55M | 8.85M | 11.42M | 12.91M |
| Operating Income | -18.43M | -19.13M | -20.60M | -28.88M | -31.75M | -34.77M |
| Net Income | -19.88M | -20.37M | -21.51M | -25.83M | -32.78M | -34.17M |
| Diluted EPS | -1.12 | -1.19 | -1.25 | -0.50 | -0.64 | -0.61 |
| R&D Expense | 3.40M | 3.51M | 3.35M | 4.00M | 4.88M | 4.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2024 | Apr 2025 |
|---|---|---|
| Revenue | 27.81M | 59.81M |
| Gross Profit | 362.00K | 24.21M |
| Operating Income | -85.06M | -106.38M |
| Net Income | -94.12M | -113.81M |
| Diluted EPS | -5.07 | -5.13 |
| R&D Expense | 15.49M | 15.65M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|
| Total Assets | - | 45.95M | 295.74M |
| Total Equity | -117.58M | -209.38M | 205.41M |
| Cash & Equivalents | - | 8.25M | 237.59M |
| Long Term Debt | - | 42.54M | 41.10M |
| Total Liabilities | - | 78.22M | 90.34M |
| Current Liabilities | - | 32.97M | 37.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2024 | Apr 2025 |
|---|---|---|
| Operating Cash Flow | -72.23M | -77.61M |
| Investing Cash Flow | -12.23M | -23.31M |
| Financing Cash Flow | 77.72M | 330.26M |
| Capital Expenditure | -12.23M | -22.94M |
| Free Cash Flow | -84.46M | -100.54M |
Ratios (Annual)
Figures in %.
| Metric | Apr 2024 | Apr 2025 |
|---|---|---|
| Gross Margin % | 1.3% | 40.5% |
| Operating Margin % | -305.8% | -177.8% |
| Net Margin % | -338.4% | -190.3% |
| ROE % | 45.0% | -55.4% |
| ROCE % | -655.4% | -41.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bain Capital Investors Llc | 43.12% | 25.17M | $689.09M |
| 2 | Price (T.Rowe) Associates Inc | 10.22% | 5.97M | $163.39M |
| 3 | FMR, LLC | 9.80% | 5.72M | $156.61M |
| 4 | Andera Partners | 4.62% | 2.70M | $73.78M |
| 5 | Yu Fan | 3.91% | 2.28M | $62.48M |
| 6 | Brown Advisory Inc. | 2.95% | 1.72M | $47.19M |
| 7 | Blackrock Inc. | 2.89% | 1.69M | $46.24M |
| 8 | Eventide Asset Management LLC | 2.48% | 1.45M | $39.58M |
| 9 | Alliancebernstein L.P. | 2.26% | 1.32M | $36.15M |
| 10 | Franklin Resources, Inc. | 2.13% | 1.24M | $34.03M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KMTS
KESTRA MEDICAL TECHNOLOGIES ($KMTS) Releases Q4 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNeWI3YzA0a19VemlwekxfYnltQXVvNHdxbGdlaTh4bWhqSWxNV2hVYXh2VG1lWEkyUVpwMDFkeVBwZXNTUWsza0QxTlpuYU1LSG9sU1gweWtVN3dpWlJJZUQ0STBuYWlSdnlpazlVdFhqZHdaV1VaWklZMW1GTFE0SUNkZXIwdWh3a2N2VU…
Kestra says ASSURE system protected 18,000 patients in FY26 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQWmlsczRhTGtWRmtwNzMxRVhISlFwdnpUTFk0NzZUdlN1Z0tPYlFsdjF5VTlzZm1Pc1lhOGZ1RWpjdV9nTWpFQlh4R190QVFlUXl4RzZ2MmdfS1dkQ29DYlZJWmVvVkhGRXk5b1llZk5MZUFwaU52Q1FTNFJjMEFScGxkU2ZadFNLcWRhdG…
Kestra Medical Technologies, Ltd. (KMTS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNb1Qwb0ZQczNCXzhqT2haYXNPT3o4Mk9ZYzlTdlFocy1zb1k1VkVHMTh3RTFQVjk1S1J1YjdpWEd5Z2xEZjk4Y1FkYXRRYTdrMmxQaXVfbWdieUloMHlyRVNCb3lMR2VFNVQxTm5uOWlLQjRYMWRuSXhFVVExOUJrTnJ5ZWtVRmNSbUJUSz…
Kestra Medical Technologies (KMTS) Reports Strong Q4 Fiscal 2026 Earnings - GuruFocus
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNNEVCeEJIZHM4OVhWSmhSMnVfM0FPQ3RsSnVETkZYQXE2T3hWVVliYVpBeTF1YUFMRUh6REdzYzhpSXo5SjRtd3BmeC1iT3ZEVmdHcVYxNGk1cVZVTk9WM0QzeDRUNmllRjJYQkgtNFR4OF94dnFoZWUzV0I5aE1jUzhzQkZObV9KQ0Y2bT…
Precision Trading with KMTS Corp (KMTS) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPazFsWGxGb2JiczUzZ3NuRlFQNlFLZnBGMmRYeHZaY1VhR0I1R1dnRG0ya2pkRmNuZWUycENHUTlFaS1lalNfOEFpeURsdzBzQXo1aWNUMXJfOFFqQldkUGJfZWNRdkNnR3FTZEktRTVScEZ5ZXpnLV9HTVU3ZWVQc3hzTmV0TUtJZWF2TU…
Earnings Flash (KMTS) Kestra Medical Technologies Posts Fiscal Q4 Per-Share Loss $0.67, vs. FactSet Est of Loss $0.59 - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNaUlaWmNkOVNmNXdWMEF6cWhMd25HQ1VRb3haaUsycmlJR3MtUE9xNUJnVUtwb3Zsa0RLdFJCb2ZweGtjNW5YV3psbmE3S0lRV2RsNm9EZmJXRzFVa1JXM1JNRUM0NHZiUlhxdl96dC0tdHd4cmNvVTlvR2JfeU9qeWRVMFNCeldzNHozRH…
KMTS — Frequently Asked Questions
What is the current share price of Kestra Medical Technologies, Ltd. (KMTS)?
As of 2026-07-14 21:23 PDT, Kestra Medical Technologies, Ltd. (KMTS) trades at $24.18 on NasdaqGS. Its 52-week range is $14.46 to $28.01.
What is the market capitalisation of KMTS?
Kestra Medical Technologies, Ltd. (KMTS) has a market capitalisation of $1.41B on NasdaqGS.
What is the P/E ratio of KMTS?
KMTS trades at a trailing price-to-earnings (P/E) ratio of -4.43. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.22.
What is the return on equity (ROE) of KMTS?
KMTS has a return on equity (ROE) of -92.65%. Its return on capital employed (ROCE) is -41.27%.
Is KMTS a good stock to buy?
This page provides a data-driven analysis of Kestra Medical Technologies, Ltd. (KMTS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.